

[Dr. Christopher Hourigan](#) DM DPhil FACP FRCP is Chief of the Laboratory of Myeloid Malignancies at the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) in Bethesda, Maryland, USA. He is co-director of the trans-NIH Myeloid Malignancies Program and a member of the Leukemia program of Johns Hopkins Hospital. Dr. Hourigan's research focuses on measurable residual disease in acute myeloid leukemia. He is co-chair of the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research (2020-2025), co-chair of the laboratory assays working group of the NCI Myeloid Malignancies Precision Medicine Initiative and a member of both the European Leukemia Network International Consensus Guidelines committee on Measurable Residual Disease in AML and the ASH Clinical Guidelines Committee for AML. After graduation from Oxford University, he completed clinical training in London and at Johns Hopkins, and is board-certified in Medicine, Oncology and Hematology. Dr. Hourigan was elected to Alpha Omega Alpha and fellowship of the Royal College of Physicians and was awarded the Young Physician-Scientist Award from the American Society for Clinical Investigation and, in 2019, the Presidential Early Career Award for Scientists and Engineers (PECASE).